Abstracts tagged "tocilizumab and uveitis"

Abstract Number: 2270 • 2018 ACR/ARHP Annual Meeting
Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Vanesa Calvo-Río², Monica Calderón Goercke², Diana Prieto Peña², Rosalía Demetrio-Pablo³, Javier Loricera³, Eva Peña Sainz-Pardo³, M. Victoria Hernández⁴, Alfredo Adan⁵, Marina Mesquida⁵, Santos Insua⁶, Jose M Herreras⁷, Olga Maíz⁸, Ana Blanco⁹, Myriam Gandía¹⁰, David Diaz-Valle¹¹, Lucía Martínez-Costa¹², Elia Valls-Pascual¹², Gisela Díaz-Cordovés¹³, Manuel Díaz-Llopis¹⁴, Inmaculada Calvo¹⁵, Ignacio Torre-Salaberri¹⁶, Antonio Atanes¹⁷, Luis Francisco Linares¹⁸, Marisa Hernández¹⁹, Emma Beltrán²⁰, Miguel Cordero-Coma²¹, Elena Aurrecoechea²², Félix Francisco²³, Raquel Almodóvar González²⁴, Oscar Ruiz Moreno²⁵, Fernando Jiménez-Zorzo²⁶, Joan Miquel Nolla²⁷, Consuelo Modesto²⁸, Enar Pons¹, Miguel Angel González-Gay³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, ⁷Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, ⁸Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ⁹Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ¹⁰Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ¹¹Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹²Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ¹³Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ¹⁴Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹⁵Hospital Universitario La Fe, Valencia, Spain, ¹⁶Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹⁷Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, ¹⁸Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁹Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ²⁰Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ²¹Ophthalmology, Hospital de León. Spain, León, Spain, ²²Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ²³Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ²⁴Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, ²⁵Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁶Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁸Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain
Background/Purpose: Cystoid macular edema (CME) is the main cause of irreversible visual loss in patients with uveitis. Our aim objective was to determine the efficacy…
Abstract Number: 2274 • 2018 ACR/ARHP Annual Meeting
Refractory and Severe Uveitic Cystoid Macular Edema Improves with Tocilizumab in Different Immune Mediated Diseases
Nuria Vegas-Revenga¹, Vanesa Calvo-Río¹, Marina Mesquida², Alfredo Adan², M. Victoria Hernández², Emma Beltrán³, Elia Valls Pascual⁴, David Diaz-Valle⁵, Gisela Díaz-Cordovés⁶, Marisa Hernandez Grafella⁷, Lucía Martínez-Costa⁸, Inmaculada Calvo⁹, Antonio Atanes¹⁰, Luis Francisco Linares¹¹, Consuelo Modesto¹², Elena Aurrecoechea¹³, Miguel Cordero-Coma¹⁴, Rosalía Demetrio-Pablo¹, Lucia C. Domínguez-Casas¹⁵, José Luis Hernández¹, Miguel Angel González-Gay¹ and Ricardo Blanco¹⁵, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ⁴Hospital Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ⁶Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ⁷Hospital Doctor Peset. Valencia. Spain, Valencia, Spain, ⁸Hospital Doctor Peset. Valencia. Spain, Valencia., Spain, ⁹Hospital Universitario La Fe, Valencia, Spain, ¹⁰Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, ¹¹Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹²Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain, ¹³Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ¹⁴Ophthalmology, Hospital de León. Spain, León, Spain, ¹⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) represents the leading cause of blindness in uveitis of different immune mediated diseases (IMD). Our aim was to evaluate the…
Abstract Number: 1169 • 2017 ACR/ARHP Annual Meeting
Rapid Improvement with Tocilizumab in Refractory and Severe Uveitic Cystoid Macular Edema
Nuria Vegas-Revenga¹, Vanesa Calvo-Río¹, Natalia Palmou-Fontana¹, Marina Mesquida², Alfredo Adan², M. Victoria Hernández², Emma Beltrán³, Elia Valls Pascual⁴, David Diaz-Valle⁵, Gisela Díaz-Cordovés⁶, Maria Luisa Hernández- Grafella⁷, Lucia Martínez- Costa⁷, Inmaculada Calvo⁸, Antonio Atanes⁹, Luis Francisco Linares¹⁰, Consuelo Modesto¹¹, Elena Aurrecoechea¹², Miguel Cordero-Coma¹³, Rosalía Demetrio-Pablo¹, Carlos Fernández-Díaz¹⁴, Lucia C. Domínguez-Casas¹⁴, José Luis Martín-Varillas¹⁴, Belén Atienza-Mateo¹⁴, Jose L. Hernández¹⁵, Miguel Angel González-Gay¹⁴ and Ricardo Blanco¹⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ⁶Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ⁷Ophthalmology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁸Hospital Universitario i Politecnico La Fe. Valencia. Spain, Valencia, Spain, ⁹Rheumatology, Complejo Hospitalario Universitario A Coruña (CHUAC). Spain, A Coruna, Spain, ¹⁰Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹¹Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain, ¹²Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ¹³Ophthalmology, Hospital de León. Spain, León, Spain, ¹⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁵Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: In uveitis, remission-inducing therapy with even more vigor than does rheumatology is mandatory. Since the eye is so much less forgiving of chronic inflammation…
Abstract Number: 2297 • 2017 ACR/ARHP Annual Meeting
Golimumab Versus Tocilizumab in Uveitis Related to Refractory Juvenile Idiopathic Arthritis. National Multicenter Study of 33 Patients
Lucia C. Domínguez-Casas¹, Vanesa Calvo-Río¹, Inmaculada Calvo², Mª Isabel González-Fernández³, Berta Lopez Montesinos³, Marina Mesquida⁴, Alfredo Adan⁴, M. Victoria Hernández⁴, Olga Maiz-Alonso⁵, Ana Blanco⁶, Antonio Atanes⁷, Beatriz Bravo⁸, Consuelo Modesto⁹, Gisela Díaz-Cordovés¹⁰, Miguel Cordero-Coma¹¹, David Diaz-Valle¹², Carlos Fernández-Cid¹³, Juan Cruz¹⁴, Oscar Ruiz Moreno¹⁵, MC Gonzalez-Vela¹⁶, Rosalía Demetrio-Pablo¹⁷, Nuria Vegas-Revenga¹, Carlos Fernández-Díaz¹, Jose L. Hernández¹⁸, Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Pediatric Rheumatology, Rheumatology. Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ³Rheumatology. Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ⁴Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, ⁶Ophtamology. Hospital Donostia. San Sebastian. Spain, San Sebastian, Spain, ⁷Rheumatology, Complejo Hospitalario Universitario A Coruña (CHUAC). Spain, A Coruna, Spain, ⁸Rheumatology. Hospital Universitario Virgen de las Nieves. Granada. Spain, Granada, Spain, ⁹Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain, ¹⁰Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹³Ophtalmology. Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ¹⁴Rheumatology. Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ¹⁵Ophthalmology and Rheumatology., Ophtalmology. Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ¹⁶Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Uveitis is a severe manifestation of Juvenil Idiopathic Arthritis (JIA). Systemic treatment is based on conventional immunosuppresants. Anti-TNFa are used in refractory cases, mainly…
Abstract Number: 2857 • 2017 ACR/ARHP Annual Meeting
Short and Long-Term Follow-up of Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis
Nuria Vegas-Revenga¹, Vanesa Calvo-Río¹, Montserrat Santos-Gómez², Inmaculada Calvo³, Mº Isabel González- Fernández³, Berta López- Montesinos³, Marina Mesquida⁴, Alfredo Adan⁴, M. Victoria Hernández⁴, Olga Maiz⁵, Antonio Atanes⁶, Beatriz Bravo⁷, Consuelo Modesto⁸, Gisela Díaz-Cordovés⁹, Natalia Palmou-Fontana¹, Javier Loricera¹, MC Gonzalez-Vela¹⁰, Rosalia Demetrio¹¹, Carlos Fernández-Díaz¹, Lucia C. Domínguez-Casas¹, José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Jose L. Hernández¹², Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ³Rheumatology, Hospital Universitario i Politecnico La Fe. Valencia. Spain, Valencia, Spain, ⁴Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Donostia. Spain, San Sebastian, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario A Coruña (CHUAC). Spain, A Coruna, Spain, ⁷Rheumatology, HU Virgen de las Nieves. Granada. Spain, Granada, Spain, ⁸Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain, ⁹Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ¹⁰Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Our objective was to assess the efficacy of tocilizumab (TCZ) at short and long term follow-up for severe juvenile idiopathic arthritis-associated uveitis.Methods: A Multicentre…
Abstract Number: 1336 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for Uveitic Cystoid Macular Edema Refractory to Other Synthetic and Biological Immunosuppressive Drugs. Multicenter Study of 25 Patients
Natalia Palmou-Fontana¹, Vanesa Calvo-Río¹, Marina Mesquida², Alfredo Adan³, M. Victoria Hernández⁴, Emma Beltran⁵, Elia Valls⁶, David Diaz-Valle⁷, Gisela Díaz-Cordovés⁸, Marisa Hernández⁹, L. Martinez-Costa¹⁰, Inmaculada Calvo¹¹, Antonio Atanes-Sandoval¹², Luis Linares¹³, Consuelo Modesto¹⁴, Elena Aurrecochea¹⁵, Miguel Cordero-Coma¹⁶, Lucia C. Domínguez-Casas¹, Carlos Fernández-Díaz¹, Miguel Angel González-Gay¹ and Ricardo Blanco¹⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Ophtalmology, Hospital Clinic, Barcelona, Spain, ³Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁷Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology, Hospital Regional Universitario (Carlos Haya). Málaga. Spain., Málaga, Spain, ⁹Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ¹⁰Hospital Dr. Peset., Valencia, Spain, ¹¹Pediatric Rheumatology, Hospital Univ. La Fe, Valencia, Spain, ¹²Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ¹³Rheumatologist, hospital de la Arrixaca, MURCIA, Spain, ¹⁴Hospital Valle de Hebron, Barcelona, Spain, ¹⁵Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹⁶Departament of Ophthalmology, Hospital de León, León, Spain, ¹⁷Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Our objective was to evaluate the efficacy and safety of Tocilizumab (TCZ) in a series of patients with refractory CME. Methods: A Multicenter…
Abstract Number: 2954 • 2016 ACR/ARHP Annual Meeting
Anti-IL6-R Tocilizumab in Refractory Uveitis Associated with BehçEt’s Disease. Multicenter Study of 11 Patients
Lucia C. Domínguez-Casas¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Emma Beltran², L. Martinez-Costa³, Elia Valls-Pascual⁴, Marisa Hernández-Garfella⁵, Antonio Atanes⁶, Miguel Cordero-Coma⁷, Joan Miquel Nolla⁸, Carmen Carrasco-Cubero⁹, Javier Loricera¹, MC Gonzalez-Vela¹⁰, Nuria Vegas-Revenga¹¹, Carlos Fernández-Díaz¹, Natalia Palmou-Fontana¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ³Hospital Dr. Peset., Valencia, Spain, ⁴Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁵Ophtamology, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ⁷Ophthalmology, Hospital de León, León, Spain, ⁸Rheumatology, Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹Rheumatology, Complejo Universitario de Badajoz, Badajoz, Spain, ¹⁰Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ¹¹Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Treatment recommended in severe and/or refractory uveitis of Behçet disease is anti-TNFα therapy, usually infliximab (IFX) or adalimumab (ADA) (Levy-Clarke et al Ophthalmology…
Abstract Number: 3042 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Uveitis Associated with Behçet’s Disease. Multicenter Study of 7 Patients.
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Emma Beltran², Antonio Atanes-Sandoval³, Enar Pons⁴, Javier Loricera¹, Carmen Gonzalez-Vela⁵, Leyre Riancho-Zarrabeitia¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ³Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ⁴Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Treatment recommended in severe and/or refractory uveitis of Behçet disease is anti-TNF-α therapy, usually infliximab (IFX) or adalimumab (ADA) (Levy-Clarke et al Ophthalmology 2014;121:785-796).…
Abstract Number: 3178 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 13 Cases
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Inmaculada Calvo², Marina Mesquida³, Alfredo Adan³, M. Victoria Hernández⁴, Olga Maiz Alonso⁵, Antonio Atanes-Sandoval⁶, Beatriz Bravo⁷, Consuelo Modesto⁸, Gisela Diaz Soriano⁹, Javier Loricera¹, Leyre Riancho-Zarrabeitia¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital La Fe, Valencia, Spain, ³Ophthalmology, Hospital Clinic, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Rheumatology, Donostia University Hospital, Donostia, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ⁷Rheumatology, Hospital Universitario HUVN, Granada, Spain, ⁸Rheumatology, Hospital HSLL, Palma de Mallorca, Spain, ⁹Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to juvenile idiopathic arthritis (JiA).Methods: Multicenter study of uveitis related to JiA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].